These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34791350)

  • 21. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
    Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
    Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.
    Resik S; Tejeda A; Diaz M; Okayasu H; Sein C; Molodecky NA; Fonseca M; Alemany N; Garcia G; Hung LH; Martinez Y; Sutter RW
    J Infect Dis; 2017 Jan; 215(2):175-182. PubMed ID: 28073858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine.
    Gamage D; Mach O; Palihawadana P; Zhang Y; Weldon WC; Oberste MS; Gunasena S; Sutter RW
    J Infect Dis; 2018 Nov; 218(12):1876-1882. PubMed ID: 29982532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
    Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
    Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
    Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.
    Gamage D; Mach O; Ginige S; Weldon WC; Oberste MS; Jeyaseelan V; Sutter RW
    J Infect Dis; 2019 May; 219(12):1887-1892. PubMed ID: 30649505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.
    Saleem AF; Mach O; Yousafzai MT; Khan A; Weldon WC; Oberste MS; Sutter RW; Zaidi AKM
    Vaccine; 2017 May; 35(24):3209-3214. PubMed ID: 28479178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
    Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
    Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.
    Saleem AF; Mach O; Quadri F; Khan A; Bhatti Z; Rehman NU; Zaidi S; Weldon WC; Oberste SM; Salama M; Sutter RW; Zaidi AK
    Vaccine; 2015 Jun; 33(24):2757-63. PubMed ID: 25917673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
    Crothers JW; Ross Colgate E; Cowan KJ; Dickson DM; Walsh M; Carmolli M; Wright PF; Norton EB; Kirkpatrick BD
    Vaccine; 2022 Apr; 40(19):2705-2713. PubMed ID: 35367069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
    Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
    Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
    Snider CJ; Zaman K; Wilkinson AL; Binte Aziz A; Yunus M; Haque W; Jones KAV; Wei L; Estivariz CF; Konopka-Anstadt JL; Mainou BA; Patel JC; Lickness JS; Pallansch MA; Wassilak SGF; Steven Oberste M; Anand A
    Vaccine; 2023 Sep; 41(41):6083-6092. PubMed ID: 37652822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.
    Grassly NC
    J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S439-46. PubMed ID: 24634499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan.
    Saleem AF; Mach O; Yousafzai MT; Khan A; Weldon WC; Steven Oberste M; Zaidi SS; Alam MM; Quadri F; Sutter RW; Zaidi AKM
    J Infect Dis; 2018 Jan; 217(3):443-450. PubMed ID: 29126173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
    Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
    Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial.
    Zaman K; Kovacs SD; Vanderende K; Aziz A; Yunus M; Khan S; Snider CJ; An Q; Estivariz CF; Oberste MS; Pallansch MA; Anand A
    Vaccine; 2021 Sep; 39(40):5814-5821. PubMed ID: 34481702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
    Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
    Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.